ArticleTherapeutic advances in neurological disorders2011
Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.
Article in Therapeutic advances in neurological disorders, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 40 citations in OpenAlex.
- Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: an observational multi-center study.Journal of neurology · 2014Trial
- Amyloid Precursor Protein and Tau Peptides Linked Together Ameliorate Loss of Cognition in an Alzheimer's Disease Animal Model.International journal of molecular sciences · 2023Article
- Drug-induced liver injury by glatiramer acetate leading to liver transplant: A case report.JGH open : an open access journal of gastroenterology and hepatology · 2023Article
- Neurodegeneration in multiple sclerosis.WIREs mechanisms of disease · 2023Review
- Macrophage reprogramming for therapy.Immunology · 2021Review
- Immediate reactions with glatiramer acetate: Diagnosis of allergy and desensitization protocols.Neurology. Clinical practice · 2020Review
- Managing Risks with Immune Therapies in Multiple Sclerosis.Drug safety · 2019Review
- The Immunomodulatory Drug Glatiramer Acetate is Also an Effective Antimicrobial Agent that Kills Gram-negative Bacteria.Scientific reports · 2017Article
- Immune Modulation in the Treatment of Amyotrophic Lateral Sclerosis: A Review of Clinical Trials.Frontiers in neurology · 2017Review
- The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.Current neurology and neuroscience reports · 2016Review
- Disease-modifying therapies and infectious risks in multiple sclerosis.Nature reviews. Neurology · 2016Review
- Risk evaluation and monitoring in multiple sclerosis therapeutics.Multiple sclerosis (Houndmills, Basingstoke, England) · 2014Review
- Review
- Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment.Patient preference and adherence · 2014Review
- Glatiramer acetate protects against inflammatory synaptopathy in experimental autoimmune encephalomyelitis.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2013Article
- Drug-Induced Liver Injury by Glatiramer Acetate Used for Treatment of Multiple Sclerosis: A Case Report.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current Multiple Sclerosis (MS) therapeutic landscape is rapidly growing. Glatiramer acetate (GA) remains unique given its non-immunosuppressive mechanism of action as well as its superior long-term safety and sustained efficacy data. In this review, we discuss proposed mechanisms of action of GA. Then we review efficacy data for reduction of relapses and slowing disability as well as long term safety data. Finally we discuss possible future directions of this unique polymer in the treatment of MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.